KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Long-Term Debt Repayments (2016 - 2025)

Charles River Laboratories International has reported Long-Term Debt Repayments over the past 17 years, most recently at $207.8 million for Q4 2025.

  • Quarterly results put Long-Term Debt Repayments at $207.8 million for Q4 2025, up 17.56% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 9.67% YoY), and the annual figure for FY2025 was $1.3 billion, down 9.67%.
  • Long-Term Debt Repayments for Q4 2025 was $207.8 million at Charles River Laboratories International, down from $253.8 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for CRL hit a ceiling of $2.5 billion in Q2 2021 and a floor of $149.4 million in Q1 2025.
  • Median Long-Term Debt Repayments over the past 5 years was $368.9 million (2022), compared with a mean of $643.5 million.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 2004.1% in 2021 and later crashed 83.41% in 2023.
  • Charles River Laboratories International's Long-Term Debt Repayments stood at $1.1 billion in 2021, then plummeted by 61.21% to $408.2 million in 2022, then decreased by 21.43% to $320.8 million in 2023, then tumbled by 44.89% to $176.8 million in 2024, then grew by 17.56% to $207.8 million in 2025.
  • The last three reported values for Long-Term Debt Repayments were $207.8 million (Q4 2025), $253.8 million (Q3 2025), and $738.3 million (Q2 2025) per Business Quant data.